menu
    • menu
    [{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Surveyor Capital"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ SVB Securities"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Inapplicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"VectivBio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by VectivBio

    Menu

    VectivBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Ironwood Pharmaceuticals

    Deal Size : $1,000.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Ironwood Announces the Completion of Squeeze-Out Merger with VectivBio

    Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : $1,000.0 million

    December 12, 2023

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Ironwood Pharmaceuticals

    Deal Size : $1,000.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Ironwood Pharmaceuticals

    Deal Size : $1,000.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering No...

    Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : $1,000.0 million

    May 22, 2023

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Ironwood Pharmaceuticals

    Deal Size : $1,000.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Immunology

    Study Phase : Phase II

    Sponsor : Asahi Kasei Pharma

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan

    Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : Inapplicable

    March 13, 2023

    Lead Product(s) : Apraglutide

    Therapeutic Area : Immunology

    Highest Development Status : Phase II

    Sponsor : Asahi Kasei Pharma

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Jefferies

    Deal Size : $125.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

    Details : VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and ...

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : Undisclosed

    October 18, 2022

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Jefferies

    Deal Size : $125.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Jefferies

    Deal Size : $125.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

    Details : VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and ...

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : Undisclosed

    October 13, 2022

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Jefferies

    Deal Size : $125.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apragluti...

    Details : Apraglutide is investigational new drug that is next-generation, long-acting synthetic GLP-2 analog being developed for range of rare gastrointestinal diseases.

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : Inapplicable

    October 13, 2022

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase I/ Phase II

    Sponsor : SVB Securities

    Deal Size : $30.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

    Details : VectivBio intends to use the net proceeds, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund clinical development and pre-commercialization activities for its lead product candidate FE203799 (Apragl...

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : Undisclosed

    June 15, 2022

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase I/ Phase II

    Sponsor : SVB Securities

    Deal Size : $30.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Asahi Kasei Pharma

    Deal Size : $200.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the C...

    Details : The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-hos...

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : $30.0 million

    March 30, 2022

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Asahi Kasei Pharma

    Deal Size : $200.0 million

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intesti...

    Details : Apraglutide, long-acting GLP-2 analog, is well-tolerated and does not require dose-adjustment in patients with renal disease, also demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available the...

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : Inapplicable

    March 29, 2022

    Lead Product(s) : Apraglutide

    Therapeutic Area : Gastroenterology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed

    VectivBio

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Apraglutide

    Therapeutic Area : Immunology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at...

    Details : Data support regenerative, non-immunosuppressive hypothesis for clinical evaluation; launched Phase 2 STARGAZE clinical study of apraglutide in steroid-refractory GI aGVHD following FDA clearance of the company’s Investigational New Drug (IND) applicat...

    Product Name : FE203799

    Product Type : Peptide

    Upfront Cash : Inapplicable

    March 23, 2022

    Lead Product(s) : Apraglutide

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth